行情

PBYI

PBYI

Puma Biotec
NASDAQ

实时行情|Nasdaq Last Sale

11.33
+0.51
+4.71%
交易中 14:20 09/23 EDT
开盘
10.72
昨收
10.82
最高
11.40
最低
10.63
成交量
60.97万
成交额
--
52周最高
48.00
52周最低
8.45
市值
4.41亿
市盈率(TTM)
-4.7067
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PBYI 新闻

  • 调查:用户对iPhone11不那么感兴趣 等待明年5G机型
  • 新浪美股.38分钟前
  • 女议员沃伦的财富税或"鼓励"富裕夫妇离婚以避税
  • 新浪美股.1小时前
  • 巨头都爱流媒体蛋糕,苹果、奈飞、迪士尼谁是赢家?
  • 新浪财经-自媒体综合.1小时前
  • 美联储威廉姆斯:我们已为上周隔夜融资动荡做好准备
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
-0.60%
制药与医学研究
-0.34%

热门股票

名称
价格
涨跌幅

PBYI 简况

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
展开

Webull提供Puma Biotechnology Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。